CMS Belgium assisted Asit Biotech, a biopharmaceutical company listed on Euronext Paris and Euronext Brussels, in the issuance of an equity line (convertible bonds) with a total commitment of EUR 12 million. The convertible bonds and subscription rights were offered through a private placement with accelerated bookbuilding. The flexible convertible bond product allowed for immediate conversion into ordinary shares and/or differed investments, insuring a continuous financing of the issuer.
In December 2017, CMS Belgium had already assisted Asit Biotech in its EUR 30 million fundraising in order to further develop its activities.
The CMS team responsible for the deal was led by Adrien Lanotte.
